Stockscreener 앱 받기
16.24
4.10%
0.64
시장 영업 전:
16.20
-0.04
-0.25%
Nurix Therapeutics Inc 주식(NRIX)의 최신 뉴스
How Weaker Q1 Results And Advancing Bexobrutideg Trials At Nurix Therapeutics (NRIX) Have Changed Its Investment Story - simplywall.st
Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide (NASDAQ:NRIX) - Seeking Alpha
Nurix Therapeutics Inc reports results for the quarter ended February 28Earnings Summary - TradingView
Portfolio Recap: Is Nurix Therapeutics Inc undervalued by DCF analysis2026 Year in Review & Safe Capital Growth Plans - baoquankhu1.vn
NRIX: Wells Fargo Adjusts Price Target while Maintaining Overwei - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Price Target Cut to $28.00 by Analysts at Wells Fargo & Company - MarketBeat
Inside Nurix Therapeutics Inc (NRIX): A Comprehensive SWOT Breakdown - GuruFocus
Nurix Therapeutics shares edge higher despite Q1 earnings miss - MSN
Nurix Therapeutics (NRIX) Stock Declines Amid Expanding Losses and R&D Investment - MEXC Exchange
Nurix Therapeutics (NRIX) Stock: Slides as Losses Widen Despite Pipeline Progress - CoinCentral
Needham & Company LLC Reaffirms "Buy" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
NRIX: Needham Reiterates Buy Rating with Target Price of $26.00 | NRIX Stock News - GuruFocus
Nurix Advances NX-5948 Into Phase 3 Head-to-Head Battle in CLL/SLL - TipRanks
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Bitget
Nurix Therapeutics, Inc. (NRIX) Posts Q1 2026 Results - AlphaStreet
Nurix Therapeutics, Inc. (NRIX) reports Q1 loss, lags revenue estimates - MSN
Nurix Therapeutics, Inc. Q1 2026 Financial Results: Continued R&D Investment, Collaboration Revenue, and Key Risk Factors Highlighted in 10-Q Filing - Minichart
Nurix Therapeutics stocks rise 3% despite Q1 miss By Investing.com - Investing.com India
Nurix Therapeutics (NRIX) Q1 FY2026 Earnings: EPS -$0.79 (Miss v - GuruFocus
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 28, 2026 - marketscreener.com
Nurix Therapeutics Reports Q1 2026 Financial Results and Corporate Update - Minichart
Nurix Therapeutics (NASDAQ:NRIX) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
NRIX Reports Lower Q1 Revenue; Focuses on Key Medical Developmen - GuruFocus
Nurix Therapeutics Fiscal Q1 Loss Widens, Revenue Falls - marketscreener.com
[10-Q] Nurix Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q1 Revenue $6.3M, vs. FactSet Est of $14.3M - marketscreener.com
Nurix Therapeutics 3Q 2026: Revenue $6.25M, EPS $(0.79) — 10-Q Summary - TradingView
Nurix Therapeutics Q1 loss widens on higher costs - TradingView
NRIX: Q1 2026 saw pipeline progress, higher R&D costs, and a strong cash position amid lower revenue - TradingView
Nurix Therapeutics (Nasdaq: NRIX) posts Q1 2026 revenue drop, wider loss - Stock Titan
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q1 Revenue $6.3M, Vs. FactSet Est of $14.3M - Moomoo
Nurix pushes leukemia drug toward full approval with Phase 3 due mid-2026 - Stock Titan
Nurix Therapeutics to Participate in Upcoming Investor Conference - Bitget
Live April 13: Nurix CEO slated for Needham healthcare webcast - Stock Titan
Nurix Therapeutics (NRIX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
U.S. Earnings Preview: After Market Close April 6 - Moomoo
Nurix Therapeutics (NASDAQ:NRIX) Trading 7.3% HigherStill a Buy? - MarketBeat
Dip Buying: Is Nurix Therapeutics Inc a stock for growth or value investorsTake Profit & Consistent Income Trade Ideas - baoquankhu1.vn
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Revenue Check: What is the next catalyst for Nurix Therapeutics Inc2026 Trading Volume Trends & Technical Entry and Exit Tips - baoquankhu1.vn
A Look At Nurix Therapeutics (NRIX) Valuation After Strong 1 Year Return And High Price To Sales Ratio - Yahoo Finance
NRIX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NRIX Technical Analysis & Stock Price Forecast - Intellectia AI
Analysts’ Top Healthcare Picks: Nurix Therapeutics (NRIX), Immunocore Holdings (IMCR) - The Globe and Mail
Nurix Therapeutics chief legal officer Ring sells $124k in stock - Investing.com Australia
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
Nurix (NRIX) legal chief sells 8,148 shares under 10b5-1 plan - Stock Titan
8,148-Share Rule 144 Notice for NRIX (NASDAQ: NRIX) - Stock Titan
Institution Moves: What is the next catalyst for Nurix Therapeutics IncPortfolio Value Report & Real-Time Sentiment Analysis - baoquankhu1.vn
HC Wainwright & Co. Maintains Nurix Therapeutics (NRIX) Buy Recommendation - MSN
Nurix Therapeutics (NASDAQ:NRIX) Shares Up 10%What's Next? - MarketBeat
Liquidity Mapping Around (NRIX) Price Events - Stock Traders Daily
Nurix Therapeutics (NRIX) moves 6.9% higher: Will this strength last? - MSN
Nurix Therapeutics : 2026 Proxy Statement vF (20260327) - marketscreener.com
Vanguard disaggregates holdings; Nurix (NRIX) beneficial ownership shown as 0% - Stock Titan
Aug Closing: Will Nurix Therapeutics Inc announce a stock splitWeekly Investment Recap & Verified Entry Point Detection - baoquankhu1.vn
Bexobrutideg data and cash position anchor Nurix (NASDAQ: NRIX) 2026 proxy - Stock Titan
Aug Breakouts: What is the long term forecast for Nurix Therapeutics Inc stockM&A Rumor & Risk Managed Investment Signals - baoquankhu1.vn
Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last? - Yahoo Finance
Nurix Therapeutics (NASDAQ:NRIX) Trading Up 10.9%Time to Buy? - marketbeat.com
Winners Losers: Is Nurix Therapeutics Inc a stock for growth or value investors2026 Key Highlights & Trade Opportunity Analysis - baoquankhu1.vn
1.57%
1.10%
자본화:
|
볼륨(24시간):